Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/AngioDynamics, Inc./ 10-Q

Quarterly Report · 10-Q

AngioDynamics, Inc.

ANGONASDAQEQUITYCurrent

Quarterly Report

Filed Oct 8, 2026Accepted Oct 8, 2026, 12:56 PM EDTCIK 1275187Accession 0001628280-26-065423
View company →Permanent SEC source ↗
Share

Company context

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. The Company’s innov ative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Current securities

ANGONASDAQ · EQUITY · Current

Recent company filings

  1. DEFA14A filingOct 8, 2026
  2. DEF 14A filingOct 8, 2026
  3. Results of Operations and Financial Condition · Regulation FD DisclosureOct 8, 2026
  4. Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 8, 2026
  5. 10-K/A filingSep 29, 2026

Registered securities in this filing

AngioDynamics, Inc. · 10-Q · Filed 2026-10-08

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Preferred Stock Purchase Rights

Symbol
No trading symbol declared
Exchange
NASDAQ
Classification
RIGHT
Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

No-trading-symbol fact: true

Common Stock, par value $.01

Symbol
ANGO
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000162828026065423 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.